AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ADMA · NASDAQ · Biotechnology

ADMA Biologics

Manufactures plasma-derived immune globulins for primary immune deficiency and hepatitis B exposure.

$9.52

After-hours close+0.17 (+1.82%)

At close$9.35(−1.37%)

Something off on this page? Send us feedback.

Profile

ADMA Biologics, Inc.ADMAHealth Care

Manufactures and markets ASCENIV and BIVIGAM intravenous immune globulins for primary humoral immunodeficiency, plus Nabi-HB for specified hepatitis B exposures. Most revenue comes from ASCENIV; an FDA-licensed Boca Raton plant, seven owned plasma centers, and contracted third-party supply support production.

Manufactures and markets ASCENIV and BIVIGAM, intravenous immune globulins for primary humoral immunodeficiency, and Nabi-HB, a hepatitis B immune globulin for specified exposures. ASCENIV, the principal commercial product, uses patented donor screening and tailored plasma pooling to incorporate high-titer antibodies against respiratory syncytial virus.

BioManufacturing handles fractionation, purification, fill-finish, commercialization, and development at an FDA-licensed facility in Boca Raton, Florida. Plasma Collection Centers operates seven FDA-licensed U.S. centers, supplying internal production and selling some source and hyperimmune plasma to third parties.

Most revenue comes from ASCENIV, and customer concentration is high. Manufacturing depends on continued FDA cGMP compliance at the Boca Raton site and reliable high-titer plasma supply from owned centers and contracted third parties.

Company facts

CEOAdam S. Grossman

ListedOct 17, 2013

ExchangeNASDAQ

HeadquartersRamsey, NJ

CountryUnited States

Employees647

CIK0001368514

ISINUS0008991046

Key statistics

Market cap$2.16B

EPS (ttm)$0.7000

P/E (ttm)13.34

ROE39.6%

P/B5.22

P/S4.23

Dividend yield—

Beta0.82vs XLV 0.93

Year to date −47.7% · Average volume (30d) 2.3M

Analysts

Price target, next 12 months$18.00+92.7%Median of 10 analysts · vs the Aug 28 close

ConsensusBuy9 of 10 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $9.34

High$21.00+124.8%

Median$18.00+92.7%

Low$17.00+82.0%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Jul 15, 2026	Mizuho Securities	Target		$24	$17
Jun 10, 2026	Raymond James	Target			$21
May 7, 2026	Canaccord Genuity	Reiterate	Buy	$21	$18
Apr 20, 2026	Canaccord Genuity	Target			$21
Apr 13, 2026	Mizuho Securities	Target		$14	$24

Earnings

EPS

Estimate$0.19

ReportedDue Nov 4, 2026

Revenue

Estimate$138.1M

ReportedDue Nov 4, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 5, 2026Q2 FY26	$0.16	$0.16	−2.0%	$125.3M	$124.4M	−0.8%	+8.64%
May 6, 2026Q1 FY26	$0.19	$0.19	−1.7%	$140.0M	$114.5M	−18.2%	−15.97%
Feb 25, 2026Q4 FY25	$0.19	$0.20	+8.1%	$139.6M	$139.2M	−0.3%	−3.19%
Nov 5, 2025Q3 FY25	$0.16	$0.16	0.0%	$139.8M	$134.2M	−4.0%	−8.72%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$114.8M	$122.0M	$134.2M	$139.2M	$114.5M	$124.4M
Gross profit	$61.1M	$67.2M	$75.6M	$88.8M	$80.8M	$86.3M
Operating income	$34.9M	$42.8M	$51.0M	$62.8M	$50.3M	$52.4M
Net income	$26.9M	$34.2M	$36.4M	$49.4M	$45.3M	$37.8M
Diluted EPS	$0.11	$0.14	$0.15	$0.20	$0.19	$0.16
Gross margin	53.2%	55.1%	56.3%	63.8%	70.5%	69.4%
Operating margin	30.4%	35.1%	38.0%	45.1%	43.9%	42.2%

Fiscal years (4-quarter sums)FY21 $80.9M · FY22 $154.1M · FY23 $258.2M · FY24 $426.5M · FY25 $510.2M

Revenue by product · FY24

ADMA BioManufacturing Segment$415.8M · 97%

Plasma Collection Centers Segment$11.3M · 3%

Revenue by geography · Q2 FY26

United States$123.3M · 99%

Non-US$1.1M · 1%

Balance sheet, Jun 30, 2026Cash & short-term investments $136.0M · Total debt $203.8M · Total assets $684.2M · Shareholders' equity $408.2M

Dividends

No dividends on record.

Ownership

Institutions 89.41%207.24M sharesInsiders 2.62%6.06M sharesOther 7.97%18.47M shares

Shares outstanding 231.77M · Float 226.72M · 97.8% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
BlackRock, Inc.	38.36M	16.55%	13F	Aug 7, 2026
State Street Corp	17.12M	7.38%	13F	Aug 7, 2026
Invesco Ltd.	11.79M	5.00%	13G	Feb 12, 2026
Vanguard Capital Management LLC	10.10M	4.36%	13F	Aug 13, 2026
Vanguard Portfolio Management LLC	10.09M	4.35%	13F	Aug 13, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
May 27, 2026	Jerrold B. Grossman	director	+6,400	$7.91
May 12, 2026	Jerrold B. Grossman	director	+12,500	$8.01
May 11, 2026	Jerrold B. Grossman	director	+12,500	$8.01
Mar 16, 2026	Adam S. Grossman	director, officer: President and CEO	−21,000	$15.16
Mar 9, 2026	Kaitlin M. Kestenberg-Messina	officer: COO and SVP, Compliance	−10,096	$15.63